Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoko Takebe

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 31, 2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPaul K Paik, Charles M Rudin, Maria C Pietanza, et al.
Cancer|May 11, 2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)Chandra P Belani, Suzanne E Dahlberg, Charles M Rudin, et al.
Oncotarget|February 23, 2018
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancerTeruo Yamauchi, Jose Rodrigo Espinosa Fernandez, Chiyo K Imamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 16, 2015
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host diseaseKristin Baird, Leora E Comis, Galen O Joe, et al.
World Journal of Oncology|January 21, 2022
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious DiseasesHiroto Nakano, Takuto Miyamoto, Yelena Y Janjigian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical UseApurva K Srivastava, Soumya Jaganathan, Laurie Stephen, et al.
Cancer|November 14, 2015
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancerAnne M Noonan, Kristen P Bunch, Jin-Qiu Chen, et al.
Cancers|June 2, 2021
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXACarter K Fairchild, Konstantinos V Floros, Sheeba Jacob, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancersJibran Ahmed, Geraldine O'Sullivan Coyne, Larry V Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part SarcomaJames Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Lung Cancer (Amsterdam, Netherlands)|May 31, 2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPaul K Paik, Charles M Rudin, Maria C Pietanza, et al.
Cancer|May 11, 2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)Chandra P Belani, Suzanne E Dahlberg, Charles M Rudin, et al.
Oncotarget|February 23, 2018
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancerTeruo Yamauchi, Jose Rodrigo Espinosa Fernandez, Chiyo K Imamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 16, 2015
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host diseaseKristin Baird, Leora E Comis, Galen O Joe, et al.
World Journal of Oncology|January 21, 2022
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious DiseasesHiroto Nakano, Takuto Miyamoto, Yelena Y Janjigian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical UseApurva K Srivastava, Soumya Jaganathan, Laurie Stephen, et al.
Cancer|November 14, 2015
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancerAnne M Noonan, Kristen P Bunch, Jin-Qiu Chen, et al.
Cancers|June 2, 2021
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXACarter K Fairchild, Konstantinos V Floros, Sheeba Jacob, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancersJibran Ahmed, Geraldine O'Sullivan Coyne, Larry V Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part SarcomaJames Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Pageof 14